Ahmed Zayed Obeidat, MD, PhD
Associate Professor
Location
- Neuroscience Center – Specialty Clinics
- 900 N. 92nd St.
- Milwaukee, WI 53226
Specialties
- Neurology
New & Established Patients Call
The key to success is teamwork. We will work together with you and your loved ones to fight MS and other neuroimmunological diseases in a personalized and comprehensive approach to best fit your needs and expectations. Remember, you are the center of our care and persistence is the key to success!
Overview
Diseases and Conditions
- Multiple Sclerosis (MS)
- Stiff Person Syndrome (SPS)
- Neuromyelitis Optica (NMO)
- Autoimmune Diseases of the Central Nervous System
- Autoimmune Encephalitis
- Neurosarcoidosis
- Anti-MOG Disease
Treatments and Services
- Neuro-Immunology
- Oral/injectable/infused and Symptomatic Therapies for Multiple Sclerosis
- Virtual Visit
Patients Ages Seen
- Adult
- Senior
Languages
- English
- Arabic
Hospital Affiliations
- Froedtert Hospital – Milwaukee
Board Certifications
- Neurology
Clinic Locations
Neuroscience Center – Specialty Clinics
- 900 N. 92nd St.
- Milwaukee, WI 53226
- (414) 805-5400
- Get Directions
Biography
Dr. Obeidat works with adults in diagnosing, treating and managing Multiple Sclerosis and Immune Disorders of the Central Nervous System. He received his medical degree with honors from the Jordan University of Science and Technology in 2008. He then joined the graduate program in neuroscience and physiology at Wright State University (WSU) in Dayton, Ohio where he received a PhD in Neuroscience and Physiology in 2013. He completed his neurology residency at the University of Cincinnati in 2017 as well as fellowship training in Demyelinating Diseases and Neuroimmunology, also from the University of Cincinnati, in 2018. Dr. Obeidat is an advocate for medical humanities and believes in the power of patient stories in shaping a successful, and a long-lasting patient-doctor relationship. In his free time, he enjoys reading and writing personal reflections and narrative medicine in its various forms.
Education and Training
Doctor of Philosophy in Biomedical Sciences (Neuroscience and Physiology) - Wright State University - Dayton, OH (2013)
Fellowship in Neuroimmunology and Multiple Sclerosis - University of Cincinnati - Cincinnati, OH (2017-2018)
Residency in Neurology - University of Cincinnati - Cincinnati, OH (2014-2017)
Publications
-
JC virus or extended interval dosing? More data are needed.
(Obeidat AZ.) Mult Scler. 2024 Nov;30(13):1698 PMID: 39240139 SCOPUS ID: 2-s2.0-85203433093 09/06/2024
-
Clinical decision support improves autoimmune/paraneoplastic antibody panel utilization.
(Nerenz RD, Hooshmand SI, Jackowiak E, Shirilla D, Yang Y, Yang K, Obeidat AZ.) Am J Clin Pathol. 2024 Sep 10 PMID: 39255415 09/10/2024
-
(Porwal MH, Razzak AN, Kumar V, Obeidat AZ, Sharma U.) Epilepsy Res. 2024 Jul;203:107382 PMID: 38761467 SCOPUS ID: 2-s2.0-85193210316 05/19/2024
-
Impact of neuromyelitis optica spectrum disorder on employment and income in the United States.
(Hjerthen IG, Trápaga Hacker C, Meador W, Obeidat AZ, Horta L, Mateen FJ.) Ann Clin Transl Neurol. 2024 Apr;11(4):1011-1020 PMID: 38374778 PMCID: PMC11021617 SCOPUS ID: 2-s2.0-85186173891 02/20/2024
-
Progressive multifocal leukoencephalopathy in patients with chronic kidney disease.
(Meylor J, Artunduaga DC, Mendoza M, Hooshmand SI, Obeidat AZ.) Neurol Sci. 2024 Apr;45(4):1619-1624 PMID: 37950135 SCOPUS ID: 2-s2.0-85176588688 11/11/2023
-
Identification and management of subclinical disease activity in early multiple sclerosis: a review.
(Ontaneda D, Chitnis T, Rammohan K, Obeidat AZ.) J Neurol. 2024 Apr;271(4):1497-1514 PMID: 37864717 PMCID: PMC10972995 SCOPUS ID: 2-s2.0-85174576757 10/21/2023
-
Increased healthcare utilization in the year before multiple sclerosis diagnosis.
(Razzak AN, Hernandez RS, Salter A, Obeidat AZ.) Mult Scler Relat Disord. 2024 Mar;83:105438 PMID: 38242052 SCOPUS ID: 2-s2.0-85183017643 01/20/2024
-
A closer look at reported colitis in association with multiple sclerosis treatments.
(Porwal MH, Obeidat AZ.) Mult Scler. 2024 Mar;30(3):453-455 PMID: 37897260 SCOPUS ID: 2-s2.0-85175354253 10/29/2023
-
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
(Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G, Frexalimab Phase 2 Trial Group.) N Engl J Med. 2024 Feb 15;390(7):589-600 PMID: 38354138 02/14/2024
-
(Obeidat AZ.) Mult Scler Relat Disord. 2024 Feb;82:105389 PMID: 38118288 SCOPUS ID: 2-s2.0-85180351134 12/21/2023
-
(Palathinkara M, Razzak AN, Ababneh OE, Cairns D, Obeidat AZ.) Mult Scler Relat Disord. 2023 Dec;80:105132 PMID: 37951095 SCOPUS ID: 2-s2.0-85176602731 11/12/2023
-
Molecular biomarkers and cognitive impairment in multiple sclerosis: A review
(Esmaeili S, Obeidat AZ, Zabeti A.) Biomarkers in Neuropsychiatry. December 2023;9 SCOPUS ID: 2-s2.0-85173250674 12/01/2023